Article info
Neurodegeneration
Original research
Newborn screening for spinal muscular atrophy with disease-modifying therapies: a cost-effectiveness analysis
- Correspondence to Dr Sophy TF Shih, Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia; sshih{at}kirby.unsw.edu.au
Citation
Newborn screening for spinal muscular atrophy with disease-modifying therapies: a cost-effectiveness analysis
Publication history
- Received February 9, 2021
- Accepted June 24, 2021
- First published July 28, 2021.
Online issue publication
November 16, 2021
Article Versions
- Previous version (28 July 2021).
- Previous version (12 August 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.